{"url_path":"/sec/cgem/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1789972/0001193125-26-229173-index.html","accession_number":"0001193125-26-229173","cik":"0001789972","ticker":"CGEM","issuer_name":"Cullinan Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1789972/0001193125-26-229173-index.html","primary_entity_key":"0001789972","primary_entity_name":"Cullinan Therapeutics, Inc."},"word_count":88,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit No.\n\n \n\nDescription\n\n99.1\n\n \n\n[Press release issued by Cullinan Therapeutics, Inc. on May 18, 2026, furnished herewith](cgem-ex99_1.htm)\n\n104\n\n \n\nCover page from this Current Report on Form 8-K, formatted in Inline XBRL\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nCULLINAN THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 18, 2026\n\nBy:\n\n/s/ Mary Kay Fenton\n\n \n\n \n\n \n\nMary Kay Fenton\nChief Financial Officer"}